CGTLive®’s Weekly Rewind – May 3, 2024

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. TMZ γδ T-Cell Regimen May Have Potential in Treating Glioblastoma

A phase 1 trial evaluating INB-200 has shown a PFS benefit in treated participants.

2. Deepak L. Bhatt, MD, MPH, MBA, on Adopting Novel Therapies into Cardiovascular Medicine

The director of the Mount Sinai Fuster Heart Hospital discussed trends in research and challenges with adopting new therapies.

3. Parkinson Gene Therapy Shows Stability, Some Improvements in On/Off Time Disease Measures

Based off these data, the phase 2 Regenerate PD trial of AB-1005 will begin enrolling later this year.

4. Amit Soni, MD, on Challenges to the Uptake of Gene Therapy for Hemophilia

The medical director of the Center for Inherited Blood Disorders discussed barriers to the widespread adoption of val-rox by the hemophilia A community.

5. Ferring Testing Bladder Cancer Gene Therapy Adstiladrin’s Mettle in Real-World Setting With ABLE-41 Observational Study

In anticipation of Bladder Cancer Awareness Month, CGTLive® has decided to take a closer look at this noninterventional real-world study.